Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benmelstobart + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Benmelstobart + gemcitabine + cisplatin is a combination chemo-immunotherapy regimen being evaluated for the first-line treatment of advanced biliary tract cancer. Benmelstobart (TQB2450) is a humanized monoclonal antibody that targets and blocks the Programmed Death-Ligand 1 (PD-L1), thereby enhancing the immune system's ability to detect and destroy tumor cells. Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by replacing cytidine during DNA replication, while cisplatin is a platinum-based chemotherapy agent that causes DNA cross-linking, leading to apoptosis. This combination aims to leverage the synergistic effects of cytotoxic chemotherapy and immune checkpoint inhibition to improve progression-free survival in patients with advanced biliary tract malignancies.
- Other names
- Benmelstobart combined with gemcitabine and cisplatin
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on benmelstobart + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benmelstobart + gemcitabine + cisplatin.